tradingview.comNov 13

Cellectis (ALCLS) Reports $101.1M Nine-Month Net Loss; Cash Runway Into H2 2028

Cellectis reported a $101.1M net loss for the nine months ended September 30, 2026, up from $41.3M in 2025, with $149M in cash and deposits. The company expects funding to last into the second half of 2028. This follows a strategic shift to in vivo gene editing and restructuring.

Original reporting

tradingview.com

Published Nov 13, 2026, 12:24 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 13, 2026, 12:36 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Cellectis (ALCLS) Reports $101.1M Nine-Month Net Loss; Cash Runway Into H2 2028 — source image — Source · tradingview.com

Decision brief

The 30-second read

Med

Why it matters

The disclosed loss and cash position highlight execution risk for the strategic realignment.

Market read

Earnings miss with cash‑runway details provides fresh material for traders assessing biotech risk.

What to watch

Potential upcoming clinical data for HEAL‑101 in H2 2027 could mitigate current cash‑burn worries.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Cellectis has been transitioning from cell therapy to in‑vivo gene editing, discontinuing legacy programs and restructuring.

Market effects

Sector

May weigh on other gene‑editing and cell‑therapy biotech peers as funding concerns spread.

Regional

Limited to US‑listed biotech investors; no broad market effect.

Global

Low global impact beyond the niche biotech sector.

Counterpoint

What could challenge this read

If the strategic shift to in‑vivo editing gains traction, the long‑term upside could outweigh short‑term cash concerns.

Key entities

company
Cellectis
French gene‑editing biotech listed on NASDAQ as ALCLS.

Read at source ← All news

MedAI 8/10

Cellectis (ALCLS) Shares Preclinical Data; Plans 2027 China IIT

Cellectis (ALCLS) shared expanded preclinical data for its APOC3 base editor, .HEAL-101, and announced plans to initiate a Phase 1 investigator-initiated trial in China, with preliminary data expected in the second half of 2027.

tradingview.comOct 27

$CLLSMedAI 8/10

One dose lowered blood fats by 75% on average in mice. Cellectis plans a China trial.

Cellectis (Nasdaq: CLLS) presented preclinical data for its .HEAL-101 gene therapy, showing 70% in vivo editing of human APOC3 and 76% triglyceride reduction in mice. The company plans a Phase 1 trial in China, with preliminary data expected in 2027. Cellectis aims to develop a one-time treatment for severe hypertriglyceridemia.

stocktitan.netOct 27

$CLLSHigh

Cellectis stock tumbles after Barclays double downgrade

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

investing.comSep 16

$CLLSMed

Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

rttnews.comAug 7

$CLLSMedAI 9/10

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Cellectis said the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company cited Phase 1 BALLI-01 data for efficacy and a manageable safety profile. Final Phase 1 results are scheduled for presentation at EHA on June 13; BALLI-01 Phase 2 enrollment is open.

manilatimes.netJun 9

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

finance.yahoo.comNov 13